Livedo reticularis following administration of ChAdOx1 nCoV-19 vaccine (AZD1222): a report of two cases
Open Access
- 30 September 2022
- journal article
- research article
- Published by Korean Vaccine Society in Clinical and Experimental Vaccine Research
- Vol. 11 (3) , 298-301
Abstract
Kim JH, et al. Clin Exp Vaccine Res. 2022 Sep;11(3):298-301. https://doi.org/10.7774/cevr.2022.11.3.298Keywords
This publication has 15 references indexed in Scilit:
- Deterioration of vaccine‐induced immune thrombotic thrombocytopenia treated by heparin and platelet transfusion: Insight from functional cytometry and serotonin release assayResearch and Practice in Thrombosis and Haemostasis, 2021
- Cutaneous thrombosis associated with skin necrosis following Oxford‐AstraZeneca COVID‐19 vaccinationClinical and Experimental Dermatology, 2021
- Pernio‐like skin lesions after the second dose of Pfizer‐BioNTech COVID‐19 vaccineJournal of the European Academy of Dermatology and Venereology, 2021
- The spectrum of COVID-19–associated dermatologic manifestations: An international registry of 716 patients from 31 countriesJournal of the American Academy of Dermatology, 2020
- Livedo reticularis: A review of the literatureIndian Dermatology Online Journal, 2015
- Reticular erythematous mucinosis – a reviewInternational Journal of Dermatology, 2012
- Livedo Reticularis and Related DisordersCurrent Treatment Options in Cardiovascular Medicine, 2011
- The Histopathological characteristics of livedo reticularisJournal of Cutaneous Pathology, 2009
- Livedo reticularis: An updateJournal of the American Academy of Dermatology, 2005
- Livedo reticularis: A form of allergic vasculitisThe Journal of Pediatrics, 1962